FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176372602> ?p ?o ?g. }

• W2176372602 endingPage "366" @default.
• W2176372602 startingPage "358" @default.
• W2176372602 abstract "The Polio Endgame strategy includes phased withdrawal of oral poliovirus vaccines (OPV) coordinated with introduction of inactivated poliovirus vaccine (IPV) to ensure population immunity. The impact of IPV introduction into a primary OPV series of immunizations in a developing country is uncertain. Between May 2011 and November 2012, we enrolled 700 Bangladeshi infant-mother dyads from Dhaka slums into an open-label randomized controlled trial to test whether substituting an injected IPV dose for the standard Expanded Program on Immunization (EPI) fourth tOPV dose at infant age 39 weeks would reduce fecal shedding and enhance systemic immunity. The primary endpoint was mucosal immunity to poliovirus at age one year, measured by fecal excretion of any Sabin virus at five time points up to 25 days post-52 week tOPV challenge, analyzed by the intention to treat principle. We randomized 350 families to the tOPV and IPV vaccination arms. Neither study arm resulted in superior intestinal protection at 52 weeks measured by the prevalence of infants shedding any of three poliovirus serotypes, but the IPV dose induced significantly higher seroprevalence and seroconversion rates. This result was identical for poliovirus detection by cell culture or RT-qPCR. The non-significant estimated culture-based shedding risk difference was −3% favoring IPV, and the two vaccination schedules were inferred to be equivalent within a 95% confidence margin of −10% to +4%. Results for shedding analyses stratified by poliovirus type were similar. Neither of the vaccination regimens is superior to the other in enhancing intestinal immunity as measured by poliovirus shedding at 52 weeks of age and the IPV regimen provides similar intestinal immunity to the four tOPV series, although the IPV regimen strongly enhances humoral immunity. The IPV-modified regimen may be considered for vaccination programs without loss of intestinal protection." @default.
• W2176372602 created "2016-06-24" @default.
• W2176372602 creator A5001819043 @default.
• W2176372602 creator A5002373459 @default.
• W2176372602 creator A5007061685 @default.
• W2176372602 creator A5010472783 @default.
• W2176372602 creator A5013167258 @default.
• W2176372602 creator A5015379338 @default.
• W2176372602 creator A5022694290 @default.
• W2176372602 creator A5030036092 @default.
• W2176372602 creator A5050404191 @default.
• W2176372602 creator A5051998945 @default.
• W2176372602 creator A5058801115 @default.
• W2176372602 creator A5066233901 @default.
• W2176372602 creator A5068198671 @default.
• W2176372602 creator A5072513067 @default.
• W2176372602 creator A5090086410 @default.
• W2176372602 date "2016-01-01" @default.
• W2176372602 modified "2023-10-16" @default.
• W2176372602 title "Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial" @default.
• W2176372602 cites W1971110767 @default.
• W2176372602 cites W1971338921 @default.
• W2176372602 cites W1986427539 @default.
• W2176372602 cites W2002366241 @default.
• W2176372602 cites W2003027106 @default.
• W2176372602 cites W2012902121 @default.
• W2176372602 cites W2020018978 @default.
• W2176372602 cites W2050906483 @default.
• W2176372602 cites W2053107945 @default.
• W2176372602 cites W2082002269 @default.
• W2176372602 cites W2092090915 @default.
• W2176372602 cites W2095998559 @default.
• W2176372602 cites W2096913021 @default.
• W2176372602 cites W2101462714 @default.
• W2176372602 cites W2102060315 @default.
• W2176372602 cites W2106168554 @default.
• W2176372602 cites W2107939515 @default.
• W2176372602 cites W2108955297 @default.
• W2176372602 cites W2109715645 @default.
• W2176372602 cites W2132518859 @default.
• W2176372602 cites W2164922917 @default.
• W2176372602 cites W2217538693 @default.
• W2176372602 cites W2313065703 @default.
• W2176372602 cites W4231125505 @default.
• W2176372602 cites W4384466965 @default.
• W2176372602 doi "https://doi.org/10.1016/j.vaccine.2015.11.046" @default.
• W2176372602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26643930" @default.
• W2176372602 hasPublicationYear "2016" @default.
• W2176372602 type Work @default.
• W2176372602 sameAs 2176372602 @default.
• W2176372602 citedByCount "10" @default.
• W2176372602 countsByYear W21763726022016 @default.
• W2176372602 countsByYear W21763726022017 @default.
• W2176372602 countsByYear W21763726022018 @default.
• W2176372602 countsByYear W21763726022019 @default.
• W2176372602 countsByYear W21763726022020 @default.
• W2176372602 countsByYear W21763726022023 @default.
• W2176372602 crossrefType "journal-article" @default.
• W2176372602 hasAuthorship W2176372602A5001819043 @default.
• W2176372602 hasAuthorship W2176372602A5002373459 @default.
• W2176372602 hasAuthorship W2176372602A5007061685 @default.
• W2176372602 hasAuthorship W2176372602A5010472783 @default.
• W2176372602 hasAuthorship W2176372602A5013167258 @default.
• W2176372602 hasAuthorship W2176372602A5015379338 @default.
• W2176372602 hasAuthorship W2176372602A5022694290 @default.
• W2176372602 hasAuthorship W2176372602A5030036092 @default.
• W2176372602 hasAuthorship W2176372602A5050404191 @default.
• W2176372602 hasAuthorship W2176372602A5051998945 @default.
• W2176372602 hasAuthorship W2176372602A5058801115 @default.
• W2176372602 hasAuthorship W2176372602A5066233901 @default.
• W2176372602 hasAuthorship W2176372602A5068198671 @default.
• W2176372602 hasAuthorship W2176372602A5072513067 @default.
• W2176372602 hasAuthorship W2176372602A5090086410 @default.
• W2176372602 hasBestOaLocation W21763726021 @default.
• W2176372602 hasConcept C106192422 @default.
• W2176372602 hasConcept C126322002 @default.
• W2176372602 hasConcept C12914427 @default.
• W2176372602 hasConcept C159047783 @default.
• W2176372602 hasConcept C168563851 @default.
• W2176372602 hasConcept C187212893 @default.
• W2176372602 hasConcept C203014093 @default.
• W2176372602 hasConcept C203092338 @default.
• W2176372602 hasConcept C22070199 @default.
• W2176372602 hasConcept C2522874641 @default.
• W2176372602 hasConcept C2777451964 @default.
• W2176372602 hasConcept C2778190748 @default.
• W2176372602 hasConcept C2779341262 @default.
• W2176372602 hasConcept C2779631682 @default.
• W2176372602 hasConcept C2908647359 @default.
• W2176372602 hasConcept C2908689829 @default.
• W2176372602 hasConcept C4870876 @default.
• W2176372602 hasConcept C71924100 @default.
• W2176372602 hasConcept C8891405 @default.
• W2176372602 hasConcept C99454951 @default.
• W2176372602 hasConceptScore W2176372602C106192422 @default.
• W2176372602 hasConceptScore W2176372602C126322002 @default.
• W2176372602 hasConceptScore W2176372602C12914427 @default.
• W2176372602 hasConceptScore W2176372602C159047783 @default.

• next